News

Scleroderma Drug Developer iBio Announces U.S. Patent for iBioModulatorâ„¢ Thermostable Immunomodulator Protein Portfolio

iBio, Inc. recently announced the release of a U.S. patent for a new thermostable immunomodulator protein portfolio called iBioModulatorâ„¢. The company’s iBioModulatorâ„¢ thermostable immunomodulator protein patents, entitled “Yersinia pests Antigens, Vaccine Compositions and Related Methods,” (Serial No. 8,945,580), includes statements about plague antigens, vaccine compositions, and a technique that produces…

New Study Explores Scleromics, the Metabolomics in Scleroderma

Three key components of systemic sclerosis (SSc) are the subject of an ongoing clinical trial in University Hospital in Strasbourg, France. “Metabolomic Analysis of Systemic Sclerosis (SCLEROMICS)” is investigating prognosis, diagnosis, and exploratory research in SSc. Current knowledge in the field lacks a system of…

Apricus Biosciences Announces Issuance Of The US Patent For Raynaud’s Phenomenon Therapy RayVa

Apricus Biosciences, Inc., a biopharmaceutical company committed to developing innovative medicines in the field of rheumatology and urology, recently announced that the United States Patent and Trademark Office (USPTO) issued the company a patent titled “Methods and compositions for treating Raynaud’s disease” with claims directed to treat Raynaud’s phenomenon. The patent will expire…

Botulinum Toxin Studied as Therapy for Scleroderma-Associated Raynaud’s Syndrome

Botulinum toxin has been very popular for reducing wrinkles and more recently for treating painful conditions. The toxin may soon have a new use for another medical condition. Johns Hopkins University researchers are studying whether botulinum toxin can provide relief to people suffering from scleroderma-associated Raynaud’s Syndrome. Scleroderma is…

SSc Patients May Improve with Grafts of Their Own Fat

Italian scientists may have identified a way to improve systemic sclerosis (SSc) symptoms with fat grafts. A recent study titled “Autologous Fat Grafting in the Treatment of Fibrotic Perioral Changes in Patients with Systemic Sclerosis” published in the journal Cell Transplantation showed that…

Lung Transplantation Poses Higher Risk for Systemic Sclerosis Patients

Researchers at Columbia University College of Physicians and Surgeons in New York reported that adults with interstitial lung disease (ILD) and systemic sclerosis (SSc) undergoing lung transplantation in the United States are almost 50% more likely to die within one year than people who have lung disease, transplantion but no…

Study Suggests Optimal Systolic Pulmonary Arterial Pressure May Increase Systemic Scleroderma Patients’ Survival Time

A multi-national team of researchers attempting to find precise clinical indicators that would increase post-diagnosis survival times among patients living with systemic scleroderma (SSc), have recently published a study with promising conclusions.  The study consisted of patients previously diagnosed with SSc from the European League Against Rheumatism Scleroderma…